FDA expands approval of Kyprolis to include combination with Darzalex Faspro and dexamethasone.
The expansion of the Kyprolis prescribing information to include Darzalex Faspro plus dexamethasone was supported by the ongoing, Phase 2, non-randomized, open-label, multicenter PLEIADES trial evaluating the clinical benefit of Darzalex Faspro administered in combination with four standard-of-care treatment regimens in patients with multiple myeloma.
Updated data from the PLEIADES study were presented at the 2020 American Society of Hematology (ASH) Annual Meeting, demonstrating that response rates with Kyprolis in combination with Darzalex Faspro and dexamethasone were similar to those in the Phase III CANDOR study (Kyprolis combined with intravenous [IV] Darzalex and dexamethasone [DKd]), which supported the first-ever approval of an anti-CD38 monoclonal antibody in combination with Kyprolis. The PLEIADES study met its primary endpoint, demonstrating an overall response rate of 84.8 percent with Darzalex Faspro-Kd.
Related news and insights
GSK Australia is pleased to announce that the Therapeutic Goods Administration (TGA) has registered Zejula (niraparib) for the treatment of women with advanced high-grade ovarian, fallopian tube or primary peritoneal cancer following completion of first-line platinum-based chemotherapy.
Bristol-Myers Squibb K.K. announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and have either experienced disease progression on the last therapy or relapse after the last therapy.